Intrinsic and treatment-related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practice

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 9, 2008, Pages 1481-1494

  Dasanu, Constantin A ^a  

^a Group Health   (United States)

Author keywords

Abnormality; Autoimmune cytopenia; Chronic lymphocytic leukaemia; Deficiency deficit; Immune alteration; Monoclonal antibody; Nucleoside analogue

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CHLORAMBUCIL; CLADRIBINE; COMPLEMENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; FLUDARABINE; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; NUCLEOSIDE ANALOG; PENTOSTATIN; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; STEROID; VALGANCICLOVIR; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANTIBODY RESPONSE; ASPERGILLOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; CYTOPENIA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; INFECTION; INFECTION SENSITIVITY; INFLUENZA; LARGE CELL LYMPHOMA; LEUKOENCEPHALOPATHY; LOW DRUG DOSE; LUNG CANCER; LYMPHOMA; MONOCYTE; MONOTHERAPY; MUCORMYCOSIS; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NEUTROPENIA; NEUTROPHIL; NONHUMAN; OPPORTUNISTIC INFECTION; PLASMAPHERESIS; PURE RED CELL ANEMIA; REVIEW; RISK FACTOR; SCREENING TEST; SECOND CANCER; SINGLE DRUG DOSE; SPLENECTOMY; T LYMPHOCYTE; TOXOPLASMOSIS; UROGENITAL TRACT CANCER; B CELL LEUKEMIA; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOPATHOLOGY;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNE TOLERANCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASMS, SECOND PRIMARY; OPPORTUNISTIC INFECTIONS;

EID: 46749087074     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.9.1481     Document Type: Review

References (69)

1. Dasanu CA, Alexandrescu DT. Risk for second nonlymphoid neoplasms in chronic lymphocytic leukemia. Med Gen Med 2007;9:35
2. Sampalo A, Navas G, Medina F, et al. Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction. Blood 2000;96:3168-74
3. Orfao A, Gonzalez M, San Miguel JF, et al. Surface phenotype and immunoglobulin levels in B-cell chronic lymphocytic leukaemia. Haematologia (Budap) 1990;23:49-56
4. Davey FR, Kurec AS, Tomar RH, et al. Serum immunoglobulins and lymphocyte subsets in chronic lymphocytic leukemia. Am J Clin Pathol 1987;87:60-5
5. Arens R, Nolte MA, Tesselaar K, et al. Signaling through CD70 regulates B cell activation and IgG production. J Immunol 2004;173:3901-8
6. Hamblin TJ, Jones JV, Peacock DB. The immune response to phichi174 in man. IV. Primary and secondary antibody production in patients with chronic lymphatic leukaemia. Clin Exp Immunol 1975;21:101-8
7. Morrison VA, Hibbs JR, Janoff EN. Systemic and mucosal immunoglobulin levels and risk of infection in patients with chronic lymphocytic leukemia and multiple myeloma. Blood 1996;88:240a
8. Burton JD, Weitz CH, Kay NE. Malignant chronic lymphocytic leukemia B cells elaborate soluble factors that down-regulate T cell and NK function. Am J Hematol 1989;30:61-7
9. Scrivener S, Goddard RV, Kaminski ER, et al. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003;44:383-9
10. Ayanlar-Batuman O, Ebert E, Hauptman SP. Defective interleukin-2 production and responsiveness by T cells in patients with chronic lymphocytic leukemia of B cell variety. Blood 1986;67:279-84
11. Perri RT, Kay NE. Abnormal T cell function in early-stage chronic lymphocytic leukemia (CLL) patients. Am J Hematol 1986;22:55-61
12. Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984;63:305-9
13. Alvarez-Mon M, Casas J, Laguna R, et al. Clinical signification of natural killer activity in B-cell chronic lymphocytic leukemia. Eur J Haematol 1987;38:268-73
14. Itala M, Vainio O, Remes K. Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia. Eur J Haematol 1996;57:46-53
15. Fust G, Czink E, Minh D, et al. Depressed classical complement pathway activities in chronic lymphocytic leukaemia. Clin Exp Immunol 1985;60:489-95
16. Schlesinger M, Broman I, Lugassy G. The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia 1996;10:1509-1513
17. Ghia P, Scielzo C, Frenquelli M, et al. From normal to clonal B cells: chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. Autoimmun Rev 2007;7:127-31
18. Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006;33:230-9
19. Duek A, Shvidel L, Braester A, et al. Clinical and immunologic aspects of B chronic lymphocytic leukemia associated with autoimmune disorders. Isr Med Assoc J 2006;8:828-31
20. Kyasa MJ, Parrish RS, Schichman SA, et al. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 2003;74:1-8
21. Mauro F, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000;95:2786-92
22. Borthakur G, O'brien S, Wierda WG, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab - incidence and predictors. Br J Haematol 2007;136:800-5
23. Pritsch O, Maloum K, Dighiero G. Basic biology of autoimmune phenomena in chronic lymphocytic leukemia. Semin Oncol 1998;25:34-41
24. Dearden C, Wade R, Else M, et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008;111:1820-6
25. D'arena G, Cascavilla N. Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Leuk Lymphoma 2007;48:1072-80
26. Diehl LF, Ketchum LH: Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998;25:80-97
27. D'arena G, Laurenti L, Capalbo S, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 2006;81:598-602
28. Pamuk GE, Turgut B, Demir M, et al. The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia. Am J Hematol 2006;81:631-3
29. Karlsson C, Hansson L, Celsing F, et al. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia 2007;21:511-4
30. Liu NS, O'brien S. Monoclonal antibodies in the treatment of chronic lymphocytic leukemia. Med Oncol 2004;21:297-304.
31. Visco C, Ruggeri M, Evangelista ML, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood 2008;111:1110-6
32. Dungarwalla M, Marsh JC, Tooze JA, et al. Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology. Ann Hematol 2007;86:191-7
33. Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol 2006;33:240-9
34. Morrison VA. Management of infectious complications in patients with chronic lymphocytic leukemia. Atlanta, Georgia, 8-11 December 2007. Hematol Am Soc Hematol Educ Program 2007;332-8
35. Morra E, Nosari A, Montillo M. Infectious complications in chronic lymphocytic leukaemia. Hematol Cell Ther 1999;41:145-51
36. Robertson LE, Pugh W, O'brien S, et al. Richter's syndrome: a report on 39 patients. J Clin Oncol 1993;11:1985-9
37. Nakamura N, Abe M. Richter syndrome in B-cell chronic lymphocytic leukemia. Pathol Int 2003;53:195-203
38. Tsimberidou AM, O'brien S, Kantarjian HM, et al. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 2006;107:1294-302
39. Callea V, Brugiatelli M, Stelitano C, et al. Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy. Leuk Lymphoma 2006;47:2314-20
40. Ravandi F, O'brien S. Immune defects in patients with chronic leukemia. Cancer Immunol Immunother 2006;55:197-209
41. Keating MJ, O'brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998;92:1165-71
42. Cheson BD, Vena DA, Barrett J, et al. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999;17:2454-60
43. Thornton PD, Bellas C, Santon A, et al. Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein - Barr virus in its pathogenesis. Leuk Res 2005;29:389-95
44. Maddocks-Christianson K, Slager SL, Zent CS, et al. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol 2007;139:398-404
45. Robak T, Blonski JZ, GORA-Tybor J, et al. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. Eur J Cancer 2004;40:383-9
46. Goodman GR, Burian C, Koziol JA, et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891-6
47. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21:1746-51
48. Keating M, O'brien S, Albitar M. Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin Oncol 2002;29:70-4
49. Glennie MJ, French RR, Cragg MS, et al. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823-37
50. O'brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-70
51. Williams ME, Densmore JJ, Pawluczkowycz AW, et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006;177:7435-43
52. Kimby E: Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-73
53. Gonzalez-Stawinski GV, Yu PB, Love SD, et al. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clin Immunol 2001;98:175-9
54. Van Der Kolk LE, Baars JW, Prins MH, et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002;100:2257-9
55. Pelosini M, Focosi D, Rita F, et al. Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature. Ann Hematol 2008;87:405-12
56. Rodig SJ, Abramson JS, Pinkus GS, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006;12:7174-9
57. Lowenstein H, Shah A, Chant A, et al. Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood. Transplant Int. 2006;19:927-36
58. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61
59. Robak T: Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk Lymphoma 2004;45:205-19
60. Elimelakh M, Dayton V, Park KS, et al. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. Haematological 2007;92:1029-36
61. Karlsson C, Hansson L, Celsing F, et al. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia 2007;21:511-4
62. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB9712). Blood 2003;101:6-14
63. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53
64. Keating MJ, O'brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-88
65. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405-11
66. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991;325:81-6.
67. Hartkamp A, Mulder AH, Rijkers GT, et al. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine 2001;19:1671-7
68. Lee S: Routine long-term follow-up of hematopoietic cell transplantation survivors. Bone Marrow Transplant. Rev Issues Hematol Oncol Immunol 2007;17:9-10
69. Weimar VM, Ceilley RI, Goeken JA. Aggressive biologic behavior of basal- and squamous-cell cancers in patients with chronic lymphocytic leukemia or chronic lymphocytic lymphoma. J Dermatol Surg Oncol 1979;5:609-14